Search research articles
Contact Us
Filters
Showing results (1-10 of 71) with videos related to
Page
of 8
Sort By:
Methods in Molecular Medicine
|
March 11, 2011
A Phase II Trial of Intratumoral Injection with a Selectively Replicating Adenovirus (ONYX-015) in Patients with Recurrent, Refractory Squamous Cell Carcinoma of the Head and Neck
D H Kirn
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 2, 2011
Redemption for the field of oncolytic virotherapy
David H Kirn
The Journal of Clinical Investigation
|
April 5, 2000
Replication-selective microbiological agents: fighting cancer with targeted germ warfare
D H Kirn
Gene Therapy
|
June 14, 2000
A tale of two trials: selectively replicating herpesviruses for brain tumors
D H Kirn
The Journal of Clinical Investigation
|
April 5, 2000
Replication-selective adenoviruses as oncolytic agents
C Heise, D H Kirn
Journal of the National Cancer Institute
|
June 5, 1996
Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma
D H Kirn, A Kramer
Molecular Medicine Today
|
December 1, 1996
Replicating viruses as selective cancer therapeutics
D H Kirn, F McCormick
Expert Opinion on Biological Therapy
|
July 23, 2004
Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus
Steve H Thorne, David H Kirn
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 18, 2005
Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development
Terry W Hermiston, D H Kirn
Nature Reviews. Cancer
|
December 24, 2008
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
David H Kirn, Steve H Thorne
Page
of 8
Search research articles
Search
Showing results (1-10 of 71) with videos related to
Sort By:
Page
of 8
Methods in Molecular Medicine
|
March 11, 2011
A Phase II Trial of Intratumoral Injection with a Selectively Replicating Adenovirus (ONYX-015) in Patients with Recurrent, Refractory Squamous Cell Carcinoma of the Head and Neck
D H Kirn
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 2, 2011
Redemption for the field of oncolytic virotherapy
David H Kirn
The Journal of Clinical Investigation
|
April 5, 2000
Replication-selective microbiological agents: fighting cancer with targeted germ warfare
D H Kirn
Gene Therapy
|
June 14, 2000
A tale of two trials: selectively replicating herpesviruses for brain tumors
D H Kirn
The Journal of Clinical Investigation
|
April 5, 2000
Replication-selective adenoviruses as oncolytic agents
C Heise, D H Kirn
Journal of the National Cancer Institute
|
June 5, 1996
Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma
D H Kirn, A Kramer
Molecular Medicine Today
|
December 1, 1996
Replicating viruses as selective cancer therapeutics
D H Kirn, F McCormick
Expert Opinion on Biological Therapy
|
July 23, 2004
Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus
Steve H Thorne, David H Kirn
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 18, 2005
Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development
Terry W Hermiston, D H Kirn
Nature Reviews. Cancer
|
December 24, 2008
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
David H Kirn, Steve H Thorne
Page
of 8